ArticleCancer research and treatment2023
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell Lymphomas.
Article in Cancer research and treatment, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- [Current status and progress in the diagnosis and treatment of monomorphic epitheliotropic intestinal T-cell lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2026Pooled it
- A genetic profiling guideline to support diagnosis and clinical management of lymphomas.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma.Blood advances · 2025Trial
- Mutation Profiling, Efficacy Monitoring, and Prognosis Evaluation Using Circulating Tumor DNA in Peripheral T-Cell Lymphoma: A Prospective, Multicenter, Observational Study.American journal of hematology · 2026Article
- Liquid biopsy for molecular profiling in cutaneous T-cell lymphoma: a pilot feasibility study.Blood neoplasia · 2026Article
- Review
- Personalized Immunotherapy for T Cell Lymphomas: From Immune Escape to Precision Therapeutics.Journal of personalized medicine · 2025Review
- Clinical implications of ctDNA-based minimal residual disease detection in newly diagnosed peripheral T-cell lymphoma: a single-center cohort study.Cell communication and signaling : CCS · 2025Article
- Circulating Tumour DNA Is a Biomarker of Response in Angioimmunoblastic T-Cell Lymphoma.International journal of molecular sciences · 2025Article
- Angioimmunoblastic T-cell lymphoma: a concise overview encompassing the pathogenetic, pathological, clinical, therapeutical characteristics, and recent advances.Clinical and experimental medicine · 2025Review
- Liquid Biopsy in B and T Cell Lymphomas: From Bench to Bedside.International journal of molecular sciences · 2025Review
- Circulating tumor DNA in lymphoma: technologies and applications.Journal of hematology & oncology · 2025Review
- Feasibility of Circulating Tumor DNA Detection in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement in Large B-Cell Lymphoma.Annals of laboratory medicine · 2025Article
- A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.Blood · 2024Review
- [Progression and application of circulating tumor DNA in lymphoma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma.Cancer research and treatment · 2024Article
- Liquid biopsy in T-cell lymphoma: biomarker detection techniques and clinical application.Molecular cancer · 2024Review
- Minimal residual disease detection in lymphoma: methods, procedures and clinical significance.Frontiers in immunology · 2024Review
- In-depth circulating tumor DNA sequencing for prognostication and monitoring in natural killer/T-cell lymphomas.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
purposePlasma circulating tumor DNA (ctDNA) could reflect the genetic alterations present in tumor tissues. However, there is little information about the clinical relevance of cell-free DNA genotyping in peripheral T-cell lymphoma (PTCL). MATERIALS AND
methodsAfter targeted sequencing plasma cell-free DNA of patients with various subtypes of PTCL (n=94), we analyzed the mutation profiles of plasma ctDNA samples and their predictive value of dynamic ctDNA monitoring for treatment outcomes.
resultsPlasma ctDNA mutations were detected in 53 patients (56%, 53/94), and the detection rate of somatic mutations was highest in angioimmunoblastic T-cell lymphoma (24/31, 77%) and PTCL, not otherwise specified (18/29, 62.1%). Somatic mutations were detected in 51 of 66 genes that were sequenced, including the following top 10 ranked genes: RHOA, CREBBP, KMT2D, TP53, IDH2, ALK, MEF2B, SOCS1, CARD11, and KRAS. In the longitudinal assessment of ctDNA mutation, the difference in ctDNA mutation volume after treatment showed a significant correlation with disease relapse or progression. Thus, a ≥ 1.5-log decrease in genome equivalent (GE) between baseline and the end of treatment showed a significant association with better survival outcomes than a < 1.5-log decrease in GE.
conclusionOur results suggest the clinical relevance of plasma ctDNA analysis in patients with PTCL. However, our findings should be validated by a subsequent study with a larger study population and using a broader gene panel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.